Company intelligence / Profile preview

ExonHit Therapeutics

Paris, Île-de-France, Franceexonhit.com ↗

Ownership: Private
Development stage: Other

Overview

ExonHit has progressed drug candidates into clinical trials mainly targeting neurodegenerative diseases such as Alzheimer's disease and oncology indications. It also develops innovative molecular diagnostic products using proprietary RNA splicing analysis technology

Therapeutic areas: OncologyNeurology
Modalities: RNA splice variant analysis technologyMolecular diagnostics assaysTherapeutic drug candidates in neurodegenerative diseases and oncologyDiagnostic DNA-based assays via acquisition of RedPath Integrated Pathology
Industry: Biotech

Partnerships

Allergan (therapeutic collaboration)Pfizer (Alzheimer's biomarker research)

Beyond the preview

Go deeper on ExonHit Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExonHit Therapeutics.